Argos Therapeutics Inc (NASDAQ:ARGS) VP Richard D. Katz sold 104,435 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.16, for a total transaction of $16,709.60. Following the completion of the sale, the vice president now owns 193,959 shares in the company, valued at approximately $31,033.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Argos Therapeutics Inc (NASDAQ ARGS) opened at $0.16 on Monday. Argos Therapeutics Inc has a fifty-two week low of $0.13 and a fifty-two week high of $5.50. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29. The stock has a market cap of $14.32, a P/E ratio of -0.13 and a beta of 1.38.
Argos Therapeutics (NASDAQ:ARGS) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter.
ILLEGAL ACTIVITY WARNING: This article was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://sportsperspectives.com/2018/01/15/argos-therapeutics-inc-args-vp-richard-d-katz-sells-104435-shares.html.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.